Patent: 9,272,052
✉ Email this page to a colleague
Summary for Patent: 9,272,052
Title: | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway |
Abstract: | The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway. |
Inventor(s): | Lewis; Timothy S. (Bothell, WA), Law; Che-Leung (Bothell, WA), McEarchern; Julie A. (Bothell, WA) |
Assignee: | SEATTLE GENETICS, INC. (Bothell, WA) |
Application Number: | 13/879,012 |
Patent Claims: | see list of patent claims |
Details for Patent 9,272,052
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Seagen Inc. | ADCETRIS | brentuximab vedotin | For Injection | 125388 | 08/19/2011 | ⤷ Try a Trial | 2030-10-22 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |